VFY Stock Chart & Stats
AU$3.20
-AU$0.02(-0.63%)
At close: 4:00 PM EDT
AU$3.20
-AU$0.02(-0.63%)
Day’s Range― - ―
52-Week RangeAU$1.15 - AU$3.91
Previous CloseN/A
Volume31.67K
Average Volume (3M)18.71K
Market Cap
AU$266.84M
Enterprise ValueAU$59.28
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Feb 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding76,240,610
10 Day Avg. Volume16,121
30 Day Avg. Volume18,715
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.68Price Target Upside46.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)AU$6.65M
Vitrafy Life Sciences Ltd. News
VFY FAQ
What was Vitrafy Life Sciences Ltd.’s price range in the past 12 months?
Vitrafy Life Sciences Ltd. lowest share price was AU$1.15 and its highest was AU$3.91 in the past 12 months.
What is Vitrafy Life Sciences Ltd.’s market cap?
Vitrafy Life Sciences Ltd.’s market cap is AU$266.84M.
When is Vitrafy Life Sciences Ltd.’s upcoming earnings report date?
Vitrafy Life Sciences Ltd.’s upcoming earnings report date is Feb 11, 2027 which is in 190 days.
How were Vitrafy Life Sciences Ltd.’s earnings last quarter?
Vitrafy Life Sciences Ltd. released its earnings results on Aug 03, 2026. The company reported -AU$0.14 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Vitrafy Life Sciences Ltd. overvalued?
According to Wall Street analysts Vitrafy Life Sciences Ltd.’s price is currently Undervalued.
Does Vitrafy Life Sciences Ltd. pay dividends?
Vitrafy Life Sciences Ltd. does not currently pay dividends.
What is Vitrafy Life Sciences Ltd.’s EPS estimate?
Vitrafy Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vitrafy Life Sciences Ltd. have?
Vitrafy Life Sciences Ltd. has 76,240,610 shares outstanding.
What happened to Vitrafy Life Sciences Ltd.’s price movement after its last earnings report?
Vitrafy Life Sciences Ltd. reported an EPS of -AU$0.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.27%.
Which hedge fund is a major shareholder of Vitrafy Life Sciences Ltd.?
Currently, no hedge funds are holding shares in AU:VFY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vitrafy Life Sciences Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$4.68 (46.09% Upside)
AU$4.68 (46.09% Upside)
Blogger Sentiment
Bullish
AU:VFY Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$17.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.19%
Trailing 12-Months
Company Description
Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited has developed cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets, cell & gene therapies, aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain software platform, and Smart Packaging systems. Vitrafy has designed and developed an innovative cryopreservation solution, which includes smart cryopreservation medical devices and packaging, and a sample quality management software platform known as LifeChain.
VFY Stock 12 Month Forecast
Average Price Target
AU$4.68
▲(46.09% Upside)
Technical Analysis
Mayne Pharma Group
―
Orthocell Ltd
―
Vita Life Sciences Limited
―
Paragon Care Limited
―
Aroa Biosurgery Ltd
―




